X
Xi Zhang
Researcher at Third Military Medical University
Publications - 75
Citations - 1527
Xi Zhang is an academic researcher from Third Military Medical University. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Bone marrow. The author has an hindex of 17, co-authored 69 publications receiving 1087 citations. Previous affiliations of Xi Zhang include University of Southern California.
Papers
More filters
Journal ArticleDOI
Engineering CAR-T cells.
TL;DR: The structure and evolution of chimeric antigen receptors are discussed, and the tools used for production of CAR-T cells are reported on, to address the challenges posed by the technology.
Journal ArticleDOI
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant.
Lan-Ping Xu,Song Jin,Shunqing Wang,Linghui Xia,Hai Bai,Sujun Gao,Qifa Liu,Jianmin Wang,Xin Wang,Ming Jiang,Xi Zhang,Depei Wu,Xiao-Jun Huang,Xiao-Jun Huang +13 more
TL;DR: Haploidentical SCT as upfront therapy was an effective and safe option for SAA patients, with favorable outcomes in experienced centers, and survival outcome for the entire population was significantly adversely associated with increased transfusions and poor performance status pre-SCT.
Journal ArticleDOI
Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord–Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation
Lei Gao,Yanqi Zhang,Baoyang Hu,Jia Liu,Peiyan Kong,Shifeng Lou,Yi Su,Tonghua Yang,Huimin Li,Yao Liu,Cheng Zhang,Li Gao,Li-dan Zhu,Qin Wen,Ping Wang,Xinghua Chen,Jiangfan Zhong,Xi Zhang +17 more
TL;DR: The findings suggest that the repeated infusion of MSCs might inhibit cGVHD symptoms in patients after HLA-haplo HSCT, accompanied by changes in the numbers and subtypes of T, B, and NK cells, leading to the acquisition of immune tolerance.
Journal ArticleDOI
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.
Xuanmao Jiao,Marco A. Velasco-Velázquez,Min Wang,Zhiping Li,Hallgeir Rui,Amy R. Peck,James E. Korkola,Xuelian Chen,Shaohua Xu,James B. DuHadaway,Sandra L. Guerrero-Rodríguez,Sankar Addya,Daniela Sicoli,Zhaomei Mu,Gang Zhang,Andres Stucky,Xi Zhang,Massimo Cristofanilli,Alessandro Fatatis,Joe W. Gray,Jiang F. Zhong,George C. Prendergast,Richard G. Pestell +22 more
TL;DR: This study offers a preclinical rationale to reposition CCR5 inhibitors to improve the treatment of breast cancer, based on their ability to enhance the tumor-specific activities of DNA-damaging chemotherapies administered in that disease.
Journal ArticleDOI
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
TL;DR: The treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications, however, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.